Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 621 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... January 8, 2024 SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests December 21, 2020 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... October 30, 2019 Can cancer cells communicate? February 28, 2023 Load more HOT NEWS Increase in Node-Positive and Stage III Breast Cancer After Two Months... Cancer in My Community: Advancements in Cancer Care in Singapore Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced...
